Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained after Double Stem Cell Transplant

Blood (2014) 124 (21): 177.

https://doi.org/10.1182/blood.V124.21.177.177

Published: 2014

Journal Articles

Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma – Interim Results From a German Multicenter Phase II Trial

Stefan Knop, MD, Christian Langer, MD, Monika Engelhardt, MD, Lars O Muegge, MD, Wolf Roesler, Albrecht Reichle, MD, Christoph Röllig, Bernd Hertenstein, MD, Martin Gramatzki, MD, Florian Bassermann, Helmut Ostermann, MD, Isrid Sturm, MD, Mark Ringhoffer, MD, Kerstin Schaefer-Eckart, MD, Sabrina Kraus, MD, Hermann Einsele, MD, Ralf C. Bargou

Blood (2013) 122 (21): 1987.

https://doi.org/10.1182/blood.V122.21.1987.1987

Published: 2013

Journal Articles

RAD (Lenalidomide, Adriamycin and Dexamethasone) Is a Novel and Very Effective Induction Regimen in Newly Diagnosed Multiple Myeloma Preceding a Risk-Adjusted Transplant Strategy,

Stefan Knop, MD, Christian Langer, MD, Monika Engelhardt, MD, Lars O Muegge, MD, Christoph Röllig, Albrecht Reichle, MD, Martin Gramatzki, Wolf Rösler, MD, Hannes Wandt, MD, Bernd Hertenstein, MD, Susanne Höppner, MD, Helmut Ostermann, MD, Isrid Sturm, MD, Tobias Dechow, MD, Mark Ringhoffer, MD, Marianne Sauerwein, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2011) 118 (21): 3967.

https://doi.org/10.1182/blood.V118.21.3967.3967

Published: 2011

Journal Articles

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Stefan Knop, MD, Christian Langer, MD, Monika Engelhardt, MD, Lars O Muegge, MD, Albrecht Reichle, MD, Christoph Röllig, MD, Martin Gramatzki, MD, Wolf Roesler, MD, Max S Topp, MD, Carmen Wesemeier, MD, Bernd Hertenstein, MD, Isrid Sturm, MD, Tobias Dechow, MD, Martin Kortüm, MD, Marianne Sauerwein, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 1945.

https://doi.org/10.1182/blood.V116.21.1945.1945

Published: 2010

Journal Articles

Sensitivity of B-CLL to Cell Death Induction by Anticancer Drugs Is Independent of the Immunoglobulin Heavy Chain Variable Genes (IgHv) Mutation Status.

Isrid Sturm, Andrew G. Bosanquet, Michael Hummel, Bernd Dorken, Peter T. Daniel

Blood (2004) 104 (11): 4426.

https://doi.org/10.1182/blood.V104.11.4426.4426

Published: 2004

Journal Articles

Expression of the Death Gene Bik/Nbk Promotes Sensitivity to Drug-Induced Apoptosis in Corticosteroid-Resistant T-Cell Lymphoma and Prevents Tumor Growth in Severe Combined Immunodeficient Mice

Peter T. Daniel, Kwok-Tao Pun, Silke Ritschel, Isrid Sturm, Jutta Holler, Bernd Dörken, Robin Brown

Blood (1999) 94 (3): 1100–1107.

https://doi.org/10.1182/blood.V94.3.1100.415a16_1100_1107

Published: 1999

Journal Articles

Immunotherapy of B-Cell Lymphoma With CD3x19 Bispecific Antibodies: Costimulation via CD28 Prevents “Veto” Apoptosis of Antibody-Targeted Cytotoxic T Cells

Peter T. Daniel, Arne Kroidl, Joachim Kopp, Isrid Sturm, Gerhard Moldenhauer, Bernd Dörken, Antonio Pezzutto

Blood (1998) 92 (12): 4750–4757.

https://doi.org/10.1182/blood.V92.12.4750

Published: 1998

NARROW

Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained after Double Stem Cell Transplant

Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma – Interim Results From a German Multicenter Phase II Trial

RAD (Lenalidomide, Adriamycin and Dexamethasone) Is a Novel and Very Effective Induction Regimen in Newly Diagnosed Multiple Myeloma Preceding a Risk-Adjusted Transplant Strategy,

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Sensitivity of B-CLL to Cell Death Induction by Anticancer Drugs Is Independent of the Immunoglobulin Heavy Chain Variable Genes (IgHv) Mutation Status.

Expression of the Death Gene Bik/Nbk Promotes Sensitivity to Drug-Induced Apoptosis in Corticosteroid-Resistant T-Cell Lymphoma and Prevents Tumor Growth in Severe Combined Immunodeficient Mice

Immunotherapy of B-Cell Lymphoma With CD3x19 Bispecific Antibodies: Costimulation via CD28 Prevents “Veto” Apoptosis of Antibody-Targeted Cytotoxic T Cells

Email alerts

ASH Publications

American Society of Hematology

Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained after Double Stem Cell Transplant

Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma – Interim Results From a German Multicenter Phase II Trial

RAD (Lenalidomide, Adriamycin and Dexamethasone) Is a Novel and Very Effective Induction Regimen in Newly Diagnosed Multiple Myeloma Preceding a Risk-Adjusted Transplant Strategy,

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Sensitivity of B-CLL to Cell Death Induction by Anticancer Drugs Is Independent of the Immunoglobulin Heavy Chain Variable Genes (IgHv) Mutation Status.

Expression of the Death Gene Bik/Nbk Promotes Sensitivity to Drug-Induced Apoptosis in Corticosteroid-Resistant T-Cell Lymphoma and Prevents Tumor Growth in Severe Combined Immunodeficient Mice

Immunotherapy of B-Cell Lymphoma With CD3x19 Bispecific Antibodies: Costimulation via CD28 Prevents “Veto” Apoptosis of Antibody-Targeted Cytotoxic T Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only